JPMorgan lowered the firm’s price target on Genmab to DKK 2,500 from DKK 3,200 and keeps an Overweight rating on the shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on GMAB:
- AbbVie (NYSE:ABBV) Slips despite New Drug Win
- Genmab announces regulatory update for epcoritamab
- Genmab Announces Positive Regulatory Updates for Epcoritamab (EPKINLY®/TEPKINLY®) for the Treatment of Relapsed/Refractory Follicular Lymphoma
- Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
- Grant of Restricted Stock Units to Board Members and Employees and Grant of Warrants to Employees in Genmab